Recon: Peter Marks joins Eli Lilly to head infectious disease unit; AstraZeneca blood pressure drug hit main goal in Phase 3 trial
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States